Anxo Pharmaceutical Co (ROCO:6677) LT-Debt-to-Total-Asset : 0.22 (As of Jun. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Anxo Pharmaceutical Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Anxo Pharmaceutical Co's long-term debt to total assests ratio for the quarter that ended in Jun. 2024 was 0.22.

Anxo Pharmaceutical Co's long-term debt to total assets ratio declined from Jun. 2023 (0.27) to Jun. 2024 (0.22). It may suggest that Anxo Pharmaceutical Co is progressively becoming less dependent on debt to grow their business.

Anxo Pharmaceutical Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Anxo Pharmaceutical Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anxo Pharmaceutical Co LT-Debt-to-Total-Asset Chart

Anxo Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.35

0.33

0.31

0.29

0.23

Anxo Pharmaceutical Co Semi-Annual Data
	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial														0.30	0.29	0.27	0.23	0.22

Anxo Pharmaceutical Co LT-Debt-to-Total-Asset Calculation

Anxo Pharmaceutical Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	499.695	/	2218.575
	=	0.23

Anxo Pharmaceutical Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (Q: Jun. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jun. 2024 )	/	Total Assets (Q: Jun. 2024 )
	=	472.507	/	2177.341
	=	0.22

Anxo Pharmaceutical Co (ROCO:6677) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Anxo Pharmaceutical Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Anxo Pharmaceutical Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Anxo Pharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Anxo Pharmaceutical Co Ltd (ROCO:6677) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

8th Floor-3, Nanjing East Road, No. 206, Section 2, Taipei City, TWN

Website

http://www.anxo.com.tw

Anxo Pharmaceutical Co Ltd is a drug manufacturer. The company is engaged in developing drugs which include prescription medication and consumer healthcare medication. The products of the company include cardiovascular system medication, central nervous system medication, diabetes medication, infectious medicine, and dermatology medication.

Anxo Pharmaceutical Co Headlines

No Headlines